Perioperative withholding of antithrombotics in cutaneous surgery may be associated with serious adverse vascular events, whereas continuing them does not significantly increase bleeding.
Does perioperative continuation of antithrombotic drugs prevent serious adverse vascular events without significantly increasing bleeding complications in patients undergoing cutaneous surgery?
Cutaneous surgeons should strongly consider perioperative continuation of patients' antithrombotic drugs to avoid serious adverse vascular events, as bleeding risk is not significantly increased.
BACKGROUND: Antithrombotic medications may increase perioperative bleeding during cutaneous surgery. Whether to discontinue these medications before surgery is controversial. OBJECTIVE: To evaluate the available evidence in order to generate preliminary guidelines regarding the perioperative use of antithrombotics. METHODS: Presentation of two cases of adverse events after preoperative discontinuation of antithrombotics, review of current anticoagulant and antiplatelet drugs, and review of the literature concerning perioperative antithrombotics in cutaneous surgery. RESULTS: Perioperative withholding of antithrombotics in cutaneous surgery may be associated with serious adverse vascular events. Continuing antithrombotics in these circumstances does not appear to significantly increase bleeding complications. The complexity of available antithrombotics makes case-by-case determinations regarding their use difficult. CONCLUSION: Cutaneous surgeons should strongly consider perioperative continuation of patients' antithrombotic drugs. The final determination should be made by the surgeon after evaluation of the circumstances and, if necessary, consultation with other experts.
Alam et al. (2002) conducted a review in Patients undergoing cutaneous surgery on antithrombotic medications (n=2). Perioperative withholding of antithrombotics vs. Continuing antithrombotics was evaluated on Serious adverse vascular events and bleeding complications. Perioperative withholding of antithrombotics in cutaneous surgery may be associated with serious adverse vascular events, whereas continuing them does not significantly increase bleeding.